More About Our Leaders
Jennifer Chan MD, MPH, is clinical director of the Neuroendocrine and Carcinoid Tumor Program at Dana-Farber and an assistant professor of Medicine at Harvard Medical School. Chan has broad expertise in the
treatment of patients with neuroendocrine tumors. In addition to her clinical practice, she has lectured widely and published numerous articles on treatment approaches for patients with pancreatic neuroendocrine and carcinoid tumors. Chan has played
a leading role in the development of novel neuroendocrine tumor therapies, and has served as the principal investigator of several investigator-initiated clinical trials. She serves on the executive committee of the North American Neuroendocrine Tumor
Society and on the Neuroendocrine Tumor Task Force of the National Cancer Institute.
Kimberly Perez, MD, is a member of the DF/HCC Gastrointestinal Oncology and Cancer Genetics and Prevention disease centers. She received her undergraduate training at Georgetown University
in Washington, DC, and received her MD from George Washington University in Washington, DC. She completed her residency and fellowship training at Rhode Island Hospital in 2010. After completing her fellowship, she joined the medical faculty at Warren
Alpert School of Medicine at Brown University and served as a Gastrointestinal Oncologist at the Comprehensive Cancer Center at Rhode Island Hospital. She joined the faculty at Dana-Farber Cancer Institute in 2015 and is currently an Assistant Professor
of Medicine at Harvard Medical School and Dana-Farber Cancer Institute.
Thomas E. Clancy, MD, is a surgical oncologist specializing in pancreaticobiliary and liver surgery at Brigham and Women's Hospital and Dana-Farber Cancer Institute, and is co-director of DF/BWCC's Pancreas and Biliary Tumor Center.
He obtained his medical degree from Harvard Medical School, followed by general surgical residency and surgical oncology fellowships at Brigham and Women's Hospital. Clancy's clinical focus is the treatment of gastrointestinal malignancies, specifically
pancreatic, biliary, and liver tumors. In addition, Clancy has a specific clinical and research interest in neuroendocrine tumors. A high-volume clinical surgical oncologist, Clancy has expertise in the surgical management of primary small intestinal
and pancreatic neuroendocrine tumors and resection of neuroendocrine tumor liver metastases. Clancy has been a leader in the development and adoption of minimally-invasive treatment techniques, including robotic pancreatectomy.
See the complete list of our gastrointestinal cancer specialists.